MDGL NASDAQ
Madrigal Pharmaceuticals, Inc.
1W: -4.9%
1M: -2.9%
3M: +18.1%
YTD: -13.5%
1Y: +75.4%
3Y: +75.8%
5Y: +281.3%
$517.26
+3.67 (+0.71%)
After Hours: $522.73 (+5.47, +1.06%)
Weekly Expected Move ±6.1%
$460
$492
$524
$555
$587
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$11.9B
52W Range265-615
Volume156,538
Avg Volume329,670
Beta-1.04
Dividend—
Analyst Ratings
Company Info
CEOWilliam J. Sibold
Employees528
SectorHealthcare
IndustryBiotechnology
IPO Date2007-02-06
Websitemadrigalpharma.com
Four Tower Bridge
West Conshohocken, PA 19428
US
West Conshohocken, PA 19428
US
267 824 2827
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Latest News
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
Earnings Scheduled For May 6, 2026
Madrigal sees 2026 gross-to-net in the mid- to high 30s while advancing F4c outcomes readout expected in 2027
Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Madrigal (MDGL) Q1 2026 Earnings Transcript
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Levy Richard S | S-Sale | 40 | $506.68 | 2026-05-22 |
| Levy Richard S | S-Sale | 320 | $508.24 | 2026-05-22 |
| Levy Richard S | S-Sale | 151 | $510.36 | 2026-05-22 |
| Levy Richard S | S-Sale | 610 | $511.40 | 2026-05-22 |
| Levy Richard S | S-Sale | 439 | $512.50 | 2026-05-22 |